Suppr超能文献

原位腺癌和微浸润腺癌亚肺叶切除术后IA期肺癌分期升级的预测因素及治疗策略

Predictors of upstage and treatment strategies for stage IA lung cancers after sublobar resection for adenocarcinoma in situ and minimally invasive adenocarcinoma.

作者信息

Su Hang, Gu Chang, She Yunlang, Xu Long, Yang Ping, Xie Huikang, Zhao Shengnan, Wu Chunyan, Xie Dong, Chen Chang

机构信息

Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.

Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.

出版信息

Transl Lung Cancer Res. 2021 Jan;10(1):32-44. doi: 10.21037/tlcr-20-828.

Abstract

BACKGROUND

Invasive adenocarcinoma intraoperatively underestimated as adenocarcinoma in situ (AIS) or minimally invasive adenocarcinoma (MIA) based on frozen section (FS) is more likely to undergo insufficient resection. We aimed to investigate the predictors of upstage and treatment strategies for stage IA invasive adenocarcinoma after sublobar resection for AIS and MIA.

METHODS

We identified 2,006 patients from January 2012 to December 2016 with early-stage lung adenocarcinoma who underwent sublobar resection based on FS diagnosis to guide surgical decision-making. All FS were categorized into three groups in real-time: (I) atypical adenomatous hyperplasia (AAH), (II) AIS, and (III) MIA.

RESULTS

A total of 272 (13.5%, 272/2,006) cases were upstaged in the final pathology (FP) diagnosis (82 AAH to AIS, 127 AIS to MIA, and nine AIS and 54 MIA to invasive adenocarcinoma), and most upstage cases (64.3%, 175/272) were attributed to sampling error. Multivariate logistic regression showed that tumor size ≥1 cm was the only independent predictor of upstage. The upstage of 209 cases to AIS or MIA had no influence on the therapy because the extent of their resection was enough. Of the 63 cases upstaged to invasive adenocarcinoma, only 13 cases agreed to receive complementary treatment: five patients underwent complementary lobectomy, and seven patients received chemotherapy. Two invasive adenocarcinoma cases without complementary treatment experienced a local recurrence after surgery. No recurrence was observed in AAH, AIS and MIA. No patient died until December 01, 2019.

CONCLUSIONS

Timely complementary treatment is encouraged in AIS/MIA upstaged to invasive adenocarcinoma based on the FP after sublobar resection to avoid local recurrence. Pathologists should be more cautious about AIS and MIA with tumor size ≥1 cm to avoid underestimation and potentially insufficient resection.

摘要

背景

基于冰冻切片(FS)术中被低估为原位腺癌(AIS)或微浸润腺癌(MIA)的浸润性腺癌更有可能切除不充分。我们旨在研究AIS和MIA行亚肺叶切除术后IA期浸润性腺癌分期上调的预测因素及治疗策略。

方法

我们纳入了2012年1月至2016年12月期间2006例接受基于FS诊断的亚肺叶切除术以指导手术决策的早期肺腺癌患者。所有FS实时分为三组:(I)非典型腺瘤样增生(AAH),(II)AIS,和(III)MIA。

结果

共有272例(13.5%,272/2006)在最终病理(FP)诊断中分期上调(82例从AAH上调为AIS,127例从AIS上调为MIA,9例AIS和54例MIA上调为浸润性腺癌),且大多数分期上调病例(64.3%,175/272)归因于取材误差。多因素logistic回归显示肿瘤大小≥1 cm是分期上调的唯一独立预测因素。209例上调为AIS或MIA的病例对治疗无影响,因为其切除范围足够。在63例上调为浸润性腺癌的病例中,只有13例同意接受补充治疗:5例患者接受了补充肺叶切除术,7例患者接受了化疗。2例未接受补充治疗的浸润性腺癌病例术后出现局部复发。AAH、AIS和MIA均未观察到复发。截至2019年12月1日无患者死亡。

结论

对于亚肺叶切除术后基于FP上调为浸润性腺癌的AIS/MIA,鼓励及时进行补充治疗以避免局部复发。病理学家对于肿瘤大小≥1 cm的AIS和MIA应更加谨慎,以避免低估和潜在的切除不充分。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0a2d/7867766/8a7b59fd1c74/tlcr-10-01-32-f1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验